Aimmune’s Palforzia adoption in peanut allergy treatment hit by COVID-19, says GlobalData

Aimmune’s Palforzia (peanut allergy powder) has seen a slower uptake due to a knock-on effect of the COVID-19 pandemic. Uptake of new drugs such as Palforzia will likely be slower than initially expected due to pandemic-related logistical challenges since patients and staff need to now follow social distancing guidelines, as reported by Manasi Vaidya, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company.

Vaidya explains: “COVID-19 has curtailed prolonged visits to the allergist office that are needed for Palforzia’s administration. Physicians have also had to limit how many patients they see at a time.

“Allergists delayed the start of Palforzia treatment once COVID-19 hit. While physicians are now keen to start Palforzia, and have adapted social distancing guidelines into their practices, the therapy protocol involves long observation periods that are now challenging compared to the pre-COVID-19 era. Patient intake is now improving, but logistical considerations requiring patients to maintain distance will continue to slow uptake. GlobalData forecasts $1.18bn in revenues for Palforzia in 2024, but analysts had previously estimated Palforzia’s revenues to reach $1.4bn that same year.”

If you would like to find out more, please send your questions to Rebecca Panks, PR Executive at GlobalData (pr@globaldata.com)

More Media